| Aptorum Group is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs. In addition, Co. is also pursuing in the therapeutic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. Co.'s Lead Projects are: ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus including but not limited to Methicillin-resistant Staphylococcus aureus; SACT-1, repurposed frug for the treatment of Neuroblastoma; and RPIDD, a molecular-based rapid pathogen identification and detection diagnostics technology. The APM YTD return is shown above.
The YTD Return on the APM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether APM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.